What is B. Riley's Forecast for CRBP FY2025 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley raised their FY2025 EPS estimates for shares of Corbus Pharmaceuticals in a research note issued on Thursday, March 13th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will post earnings per share of ($3.70) for the year, up from their prior estimate of ($5.60). The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals' Q4 2025 earnings at ($0.92) EPS, FY2026 earnings at ($3.14) EPS and FY2027 earnings at ($3.27) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.24.

CRBP has been the topic of a number of other research reports. StockNews.com raised Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday, March 6th. William Blair started coverage on Corbus Pharmaceuticals in a research note on Friday, February 28th. They issued an "outperform" rating for the company. Jefferies Financial Group dropped their price target on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective (down from $75.00) on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. Finally, Piper Sandler began coverage on Corbus Pharmaceuticals in a report on Monday, December 2nd. They set an "overweight" rating and a $35.00 price target for the company. One research analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $59.13.

Remove Ads

Corbus Pharmaceuticals Stock Down 2.0 %

Shares of NASDAQ:CRBP traded down $0.12 during midday trading on Monday, reaching $5.91. The company had a trading volume of 244,587 shares, compared to its average volume of 365,745. The business's 50 day moving average price is $9.06 and its 200 day moving average price is $17.63. The stock has a market cap of $72.29 million, a PE ratio of -1.26 and a beta of 2.63. Corbus Pharmaceuticals has a 1-year low of $5.88 and a 1-year high of $61.90.

Institutional Trading of Corbus Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Victory Capital Management Inc. increased its stake in shares of Corbus Pharmaceuticals by 29.9% during the third quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company's stock valued at $511,000 after buying an additional 5,700 shares during the period. HealthInvest Partners AB grew its stake in Corbus Pharmaceuticals by 77.9% in the third quarter. HealthInvest Partners AB now owns 69,573 shares of the biopharmaceutical company's stock valued at $1,435,000 after purchasing an additional 30,473 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Corbus Pharmaceuticals by 224.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company's stock valued at $1,932,000 after purchasing an additional 64,800 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Corbus Pharmaceuticals by 7.6% in the third quarter. The Manufacturers Life Insurance Company now owns 22,731 shares of the biopharmaceutical company's stock valued at $469,000 after purchasing an additional 1,600 shares during the last quarter. Finally, FMR LLC grew its stake in Corbus Pharmaceuticals by 33.0% in the third quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company's stock valued at $207,000 after purchasing an additional 2,486 shares during the last quarter. 64.64% of the stock is currently owned by institutional investors.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.